David Zaccardelli, Verona Pharma CEO
January 2, 2024 05:56 AM ESTUpdated 06:37 AM
Financing
R&D

Verona se­cures $400M fi­nanc­ing arrange­ment with Ox­ford, Her­cules as en­sifen­trine PDU­FA date inch­es clos­er

Ayisha Sharma

News Reporter

Verona Phar­ma has inked a debt fi­nanc­ing deal worth up to $400 mil­lion with Ox­ford Fi­nance and Her­cules Cap­i­tal as it pre­pares for the po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times